{"product_id":"akebia-five-forces-analysis","title":"Akebia Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAkebia faces moderate buyer power, specialized supplier influence, and significant competitive rivalry as it navigates reimbursement pressures and patent cliffs in renal care markets.\u003c\/p\u003e\n\u003cp\u003eRegulatory scrutiny and high development costs raise barriers for new entrants but also heighten substitute threats from emerging therapies and generics.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Akebia’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API Contract Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpakebia relies on third-party contract manufacturing organizations for vadadustat and ferric citrate api production in about of commercial capacity was outsourced industry-wide concentrating supply. the technical complexity strict cgmp rules mean fewer than global suppliers can scale to metric tons annually raising qualification costs near per facility. this supplier concentration gives manufacturers moderate leverage pricing timelines akebia faced a reported week lead-time variance impacting cogs sensitivity. what estimate hides: dual-sourcing or vertical integration could cut timeline risk but add capital spend.\u003e\n\u003c\/pakebia\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpakebia must partner with global clinical research organizations to run post studies and new trials switching mid can add months millions data show median delay of incremental costs cros patient networks validated systems concentrate leverage especially for rare nephrology where site activation rates fall under their role makes them powerful suppliers affecting timeline cost regulatory risk.\u003e\n\u003c\/pakebia\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Technology Licensors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia relies on licensed HIF-PHI technologies and foundational patents that drive its vadadustat program; licensors wield leverage via royalty rates—industry-standard biopharma royalties range 2–10%—and litigation risk that can halt commercialization.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Akebia's freedom to operate hinges on these agreements and milestone payments (recent deals show upfronts $5–50M), so maintaining licenses and defensive patent strategies is critical to avoid injunctions and revenue loss.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Logistics and Cold Chain Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized logistics and cold chain providers hold strong bargaining power for Akebia because only a small pool meet FDA, EU GDP, and FDA Drug Supply Chain Security Act standards required for biopharmaceuticals; in 2024, ~65% of US pharma cold shipments used top-tier certified carriers, concentrating leverage.\u003c\/p\u003e\n\u003cp\u003eService disruptions—like TempControl carrier outages in Q3 2023—can cause drug shortages and revenue hits; a single-week cold-chain failure can cost a mid-size specialty drug maker $5–10M in lost sales and spoilage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew certified distributors: ~65% market share by top-tier carriers (2024)\u003c\/li\u003e\n\u003cli\u003eHigh impact: 1-week failure ≈ $5–10M revenue loss\u003c\/li\u003e\n\u003cli\u003eRegulatory burden raises switching costs and supplier leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Consultants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNiche regulatory consultants for FDA and EMA kidney-disease approvals command strong supplier power: their specialized expertise is critical to secure and expand labels, and firms pay high fees—consulting rates often range from $300–$800\/hour and program fees $250k–$2M per submission in 2024–2025.\u003c\/p\u003e\n\u003cp\u003eThe power reflects high stakes of regulatory failure—median FDA nephrology review times were ~10.8 months in 2024—and a small pool of senior experts, concentrating bargaining leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh fees: $300–$800\/hour; $250k–$2M per submission\u003c\/li\u003e\n\u003cli\u003eLong reviews: median FDA nephrology review ~10.8 months (2024)\u003c\/li\u003e\n\u003cli\u003eLimited talent: few senior regulatory leads globally\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration and service bottlenecks = major cost, delay \u0026amp; royalty risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-strong power: API\/CMO concentration (fewer than 10 global scale suppliers; $5–10M qualification; 8–12 week lead variance), CROs create 8–14 month delays\/$5–20M extra, licensors demand 2–10% royalties and $5–50M upfronts, cold-chain\/top carriers ~65% share (2024) with 1-week failure ≈ $5–10M loss, regulatory consultants $300–$800\/hr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\/CMO\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10 suppliers; $5–10M qual\u003c\/td\u003e\n\u003ctd\u003ePrice\/timeline risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003e8–14mo; $5–20M\u003c\/td\u003e\n\u003ctd\u003eTrial delay\/cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUncovers key drivers of competition, buyer and supplier power, threat of substitutes and new entrants specifically for Akebia, highlighting disruptive forces, pricing pressures, and strategic levers to protect or grow market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces for Akebia—one-sheet clarity to spot competitive risks and relief strategies fast, ready to drop into decks or stress-test across scenarios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Dialysis Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMajor providers DaVita Inc. and Fresenius Medical Care control roughly 70% of U.S. in-center dialysis capacity (2024), making them primary gatekeepers for Akebia Therapeutics’ Vafseo (vadadustat). \u003c\/p\u003e\n\u003cp\u003eTheir scale lets them demand deep volume discounts and preferred pricing at renewals—contracts often tilt pricing down 20–40% versus list. \u003c\/p\u003e\n\u003cp\u003eInclusion on these chains’ formularies is make-or-break: winning both could cover an estimated 60–80% of commercial U.S. dialysis demand; losing either sharply limits uptake. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Payors and Medicare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA vast majority of end-stage renal disease patients—about 84% in 2023—are covered by Medicare, giving the federal government major leverage over reimbursement rates and making payor policy a key revenue driver for Akebia Therapeutics. Changes to the Medicare bundled payment or the End-Stage Renal Disease Prospective Payment System (ESRD PPS), last updated materially in 2021 with annual adjustments, can shift incentives for using Akebia’s vadadustat by altering clinic margins. Akebia must align pricing to Medicare caps—ESRD PPS base rate was roughly $260 per dialysis treatment in 2024—so reimbursement cuts or bundle expansions could compress uptake and clinic preference. This forces continuous payer engagement, pricing flexibility, and scenario planning to keep therapies economically viable for dialysis providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePBMs negotiate drug tier placement for private insurers and can demand large rebates; in 2024 the top three PBMs (CVS Caremark, Express Scripts, OptumRx) managed ~80% of commercial lives, giving them outsized leverage over Akebia’s CKD non-dialysis drugs.\u003c\/p\u003e\n\u003cp\u003eFailure to secure preferred formulary status with major PBMs can cut off access to ~60–70% of commercially insured CKD patients, and rebates of 20–50% can materially compress Akebia’s net price and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpgroup purchasing organizations aggregate buying for\u003e1,000 US hospitals, often capturing 30–40% price concessions on drugs; this scale lets them push Akebia Pharmaceuticals (Akebia Therapeutics, Inc.) into lower margins to keep hospital formularies.\n\u003cpby forcing price transparency and competitive bidding gpos raise churn risk for branded renal anemia drugs in gpo-driven contracts cut asp-based reimbursements by roughly hospital channels.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eGPOs: large buying pools, strong leverage\u003c\/li\u003e\u003cli\u003eImpact: 30–40% aggregate discounts common\u003c\/li\u003e\u003cli\u003eAkebia risk: 5–15% margin pressure in hospitals (2024)\u003c\/li\u003e\n\u003c\/pby\u003e\u003c\/pgroup\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Health Systems and Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLarge integrated health systems like Kaiser Permanente and CommonSpirit increasingly centralize purchasing using comparative effectiveness and cost-benefit analyses; in 2024, hospital systems drove ~60% of US inpatient drug purchasing decisions, favoring protocols that prioritize lower-cost or established treatments over new branded therapies.\u003c\/p\u003e\n\u003cp\u003eAkebia must supply robust health economic outcomes—real-world evidence, cost-per-QALY models, and budget-impact analyses—showing long-term savings versus ESAs and transfusions to win formulary placement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% of inpatient drug buys by systems (2024)\u003c\/li\u003e\n\u003cli\u003eProtocols favor lower-cost\/established care\u003c\/li\u003e\n\u003cli\u003eRequire cost-per-QALY and budget-impact data\u003c\/li\u003e\n\u003cli\u003eReal-world evidence + long-term safety essential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyer oligopoly forces Akebia into 20–50% rebates, deep discounts, and heavy evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge dialysis chains (DaVita, Fresenius ~70% 2024) plus Medicare (covers ~84% ESRD 2023; ESRD PPS ~$260\/treatment in 2024), top PBMs (~80% lives) and GPOs (30–40% discounts; 5–15% hospital margin pressure 2024) hold strong leverage, forcing Akebia to accept 20–50% rebates, deep discounts, and produce robust health‑economic evidence to secure formulary access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact on Akebia\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDaVita\/Fresenius\u003c\/td\u003e\n\u003ctd\u003e~70% in‑center capacity\u003c\/td\u003e\n\u003ctd\u003ePreferred formulary = 60–80% demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare (ESRD)\u003c\/td\u003e\n\u003ctd\u003e~84% ESRD covered; PPS ~$260\u003c\/td\u003e\n\u003ctd\u003eSets reimbursement cap, shifts margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop PBMs\u003c\/td\u003e\n\u003ctd\u003e~80% commercial lives\u003c\/td\u003e\n\u003ctd\u003eRebates 20–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\u003c\/td\u003e\n\u003ctd\u003e30–40% discounts\u003c\/td\u003e\n\u003ctd\u003e5–15% hospital margin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAkebia Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Akebia Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders, no mockups.\u003c\/p\u003e\n\u003cp\u003eThe document displayed is the full, professionally formatted analysis ready for download and use the moment you buy; what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747271127417,"sku":"akebia-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/akebia-five-forces-analysis.png?v=1772196938","url":"https:\/\/matrixbcg.com\/products\/akebia-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}